[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013015147A - Procesos y compuestos intermediarios para producir azaindoles. - Google Patents

Procesos y compuestos intermediarios para producir azaindoles.

Info

Publication number
MX2013015147A
MX2013015147A MX2013015147A MX2013015147A MX2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A MX 2013015147 A MX2013015147 A MX 2013015147A
Authority
MX
Mexico
Prior art keywords
intermediates
processes
azaindoles
producing
jak
Prior art date
Application number
MX2013015147A
Other languages
English (en)
Inventor
Adam Looker
Gerald J Tanoury
Young Chun Jung
Derek Magdziak
Brillie J Kline
Václav Jurcik
Beatriz Dominguez Olmo
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2013015147A publication Critical patent/MX2013015147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a procesos y productos intermediarios para la preparación de compuestos útiles como inhibidores de cinasas Janus (JAK).
MX2013015147A 2011-07-05 2012-07-03 Procesos y compuestos intermediarios para producir azaindoles. MX2013015147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504351P 2011-07-05 2011-07-05
US201261636296P 2012-04-20 2012-04-20
PCT/US2012/045431 WO2013006634A2 (en) 2011-07-05 2012-07-03 Processes and intermediates for producing azaindoles

Publications (1)

Publication Number Publication Date
MX2013015147A true MX2013015147A (es) 2014-03-27

Family

ID=46513874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015147A MX2013015147A (es) 2011-07-05 2012-07-03 Procesos y compuestos intermediarios para producir azaindoles.

Country Status (19)

Country Link
US (5) US8513414B2 (es)
EP (2) EP3141548B9 (es)
JP (3) JP2014520815A (es)
KR (1) KR20140058547A (es)
CN (2) CN103702998A (es)
AR (1) AR087069A1 (es)
AU (1) AU2012279046B2 (es)
BR (1) BR112014000115A2 (es)
CA (1) CA2839937C (es)
DK (1) DK3141548T3 (es)
ES (1) ES2804528T3 (es)
MX (1) MX2013015147A (es)
NZ (2) NZ714502A (es)
PL (1) PL3141548T3 (es)
PT (1) PT3141548T (es)
RU (1) RU2014103806A (es)
TW (1) TW201321378A (es)
WO (1) WO2013006634A2 (es)
ZA (1) ZA201400049B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676285A (zh) * 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
SI2442809T1 (sl) 2009-06-17 2017-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov gripe
EP3141548B9 (en) 2011-07-05 2020-08-12 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
EP3036225A1 (en) 2013-08-22 2016-06-29 Vertex Pharmaceuticals Incorporated Isotopically enriched azaindoles
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
CN105849105B (zh) * 2013-11-13 2018-02-13 沃泰克斯药物股份有限公司 制备流感病毒复制抑制剂的方法
CA2930103A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN106854205B (zh) * 2015-12-09 2019-07-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN105523986A (zh) * 2015-12-30 2016-04-27 江汉大学 一种外排泵抑制剂n-氢-2-芳基吲哚及其衍生物的合成方法
HRP20210145T1 (hr) * 2016-09-09 2021-03-05 F. Hoffmann - La Roche Ag Postupak za dobivanje 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-b;3',4'-d]pirola
US10577365B2 (en) 2016-12-23 2020-03-03 Felicitex Therapeutics, Inc. Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
KR20210132007A (ko) * 2018-12-24 2021-11-03 치아타이 티안큉 파마수티컬 그룹 주식회사 피롤로피리미딘 화합물의 치료 용도 및 피롤로피리미딘 화합물의 고체 약학적 조성물
CN113121452A (zh) * 2021-05-10 2021-07-16 甘肃堡昌化工有限公司 一种硫酸法尿嘧啶的精制工艺
CN113851244A (zh) * 2021-09-18 2021-12-28 浙江爱索拓科技有限公司 一种含放射性同位素碳-14废水的处理方法
CN113896716A (zh) * 2021-10-27 2022-01-07 浙江爱索拓科技有限公司 一种放射性同位素碳-14双标记甲磺酸伏美替尼合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
CA2482838A1 (en) 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
WO2005033072A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Heterocyclic amides and sulfonamides
CA2549431C (en) 2004-01-30 2010-09-14 Nagase & Co., Ltd. Optically active quaternary ammonium salt having axial asymmetry and process for producing .alpha.-amino acid and derivative thereof with the same
CN101676285A (zh) 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
WO2006038001A1 (en) * 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
NZ592968A (en) 2006-01-17 2012-08-31 Vertex Pharma Azaindoles substituted with either triazine or pyrimidine useful as inhibitors of janus kinases consisting of JAK1, JAK2, JAK3, and TYK2
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
MY145385A (en) * 2006-08-08 2012-01-31 Chugai Pharmaceutical Co Ltd Pyrimidine derivative as p13k inhibitor and use thereof
ATE497961T1 (de) 2006-12-14 2011-02-15 Vertex Pharma Als proteinkinaseinhibitoren geeignete verbindungen
EP2207775B1 (en) * 2007-11-05 2012-03-21 Novartis AG 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
DK2247592T3 (da) * 2008-02-25 2011-09-26 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitors
SI2442809T1 (sl) 2009-06-17 2017-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov gripe
EP3141548B9 (en) 2011-07-05 2020-08-12 Vertex Pharmaceuticals Incorporated Processes and intermediates for producing azaindoles
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX2014005565A (es) 2011-11-07 2014-05-30 Vertex Pharma Metodos para tratar enfermedades inflamatorias y composiciones farmaceuticas utiles para los mismos.
EP3036225A1 (en) 2013-08-22 2016-06-29 Vertex Pharmaceuticals Incorporated Isotopically enriched azaindoles

Also Published As

Publication number Publication date
DK3141548T3 (da) 2020-07-06
US20150284388A1 (en) 2015-10-08
CA2839937A1 (en) 2013-01-10
WO2013006634A3 (en) 2013-05-10
US8513414B2 (en) 2013-08-20
CN103702998A (zh) 2014-04-02
TW201321378A (zh) 2013-06-01
EP3141548B9 (en) 2020-08-12
KR20140058547A (ko) 2014-05-14
EP3141548A1 (en) 2017-03-15
BR112014000115A2 (pt) 2016-10-04
JP6761448B2 (ja) 2020-09-23
US8796453B2 (en) 2014-08-05
PT3141548T (pt) 2020-07-10
EP2729465A2 (en) 2014-05-14
AU2012279046A1 (en) 2014-01-23
US8946425B2 (en) 2015-02-03
AR087069A1 (es) 2014-02-12
US20130102782A1 (en) 2013-04-25
US20130303764A1 (en) 2013-11-14
PL3141548T3 (pl) 2020-09-07
WO2013006634A9 (en) 2013-03-21
ES2804528T3 (es) 2021-02-08
RU2014103806A (ru) 2015-08-10
NZ619699A (en) 2016-03-31
CN106432311A (zh) 2017-02-22
ZA201400049B (en) 2015-04-29
US20150099884A1 (en) 2015-04-09
CA2839937C (en) 2020-11-03
EP3141548B1 (en) 2020-04-08
JP2014520815A (ja) 2014-08-25
JP2018162314A (ja) 2018-10-18
WO2013006634A2 (en) 2013-01-10
AU2012279046B2 (en) 2017-08-31
US20140309421A1 (en) 2014-10-16
JP2017002067A (ja) 2017-01-05
NZ714502A (en) 2017-04-28
US9090614B2 (en) 2015-07-28

Similar Documents

Publication Publication Date Title
MX2013015147A (es) Procesos y compuestos intermediarios para producir azaindoles.
PH12015502839B1 (en) Antiviral compounds
TW201240990A (en) Antiviral compounds
SI2697218T1 (sl) Postopek za pripravo spojin, koristnih kot zaviralci sglt2
AU2012213775A8 (en) 7-azaindole derivatives
WO2012107778A3 (en) Mutant pores
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
MX2020011251A (es) Compuestos antivirales.
IN2014KN01491A (es)
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
NZ711192A (en) Process for making benzoxazepin compounds
IN2014KN01062A (es)
ZA201301799B (en) Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
IN2014MN01671A (es)
HK1201067A1 (en) Sialic acid analogs
GB201107985D0 (en) Process
EP2882744B8 (en) Process for the preparation of c-fms kinase inhibitors
MX337610B (es) Proceso para la preparacion de (r)-2-acetamido-n-bencil-3-metoxipr opionamida e intermediarios de la misma.
MX2014002630A (es) Produccion de alcaloides sin el aislamiento de compuestos intermediarios.
IN2012DN03040A (es)
MY168958A (en) Intermediates and processes for preparing compounds
HK1192754A (en) Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal